These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

937 related articles for article (PubMed ID: 14994384)

  • 1. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts.
    Kubota A; Hasegawa K; Suguro T; Koshihara Y
    J Rheumatol; 2004 Mar; 31(3):426-35. PubMed ID: 14994384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
    Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
    Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
    Dai SM; Nishioka K; Yudoh K
    Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
    Wada N; Maeda H; Yoshimine Y; Akamine A
    Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls.
    Vanderborght A; Linsen L; Thewissen M; Geusens P; Raus J; Stinissen P
    J Rheumatol; 2004 Aug; 31(8):1483-90. PubMed ID: 15290725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients.
    Kotake S; Udagawa N; Hakoda M; Mogi M; Yano K; Tsuda E; Takahashi K; Furuya T; Ishiyama S; Kim KJ; Saito S; Nishikawa T; Takahashi N; Togari A; Tomatsu T; Suda T; Kamatani N
    Arthritis Rheum; 2001 May; 44(5):1003-12. PubMed ID: 11352231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of synovial cell clones isolated from rheumatoid arthritis patients: possible involvement of TNF-alpha in reduction of osteoprotegerin in synovium.
    Zhao B; Takami M; Miyamoto Y; Suzawa T; Yamada A; Mochizuki A; Yasuhara R; Wang X; Inoue T; Namiki O; Sakamoto K; Kamijo R
    Cytokine; 2008 Jan; 41(1):61-70. PubMed ID: 18083042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of RANK, RANK-L, and osteoprotegerin by synovial fluid neutrophils from patients with rheumatoid arthritis and by healthy human blood neutrophils.
    Poubelle PE; Chakravarti A; Fernandes MJ; Doiron K; Marceau AA
    Arthritis Res Ther; 2007; 9(2):R25. PubMed ID: 17341304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium.
    Hou WS; Li W; Keyszer G; Weber E; Levy R; Klein MJ; Gravallese EM; Goldring SR; Brömme D
    Arthritis Rheum; 2002 Mar; 46(3):663-74. PubMed ID: 11920402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic implications for interferon-alpha in arthritis: a pilot study.
    Wong T; Majchrzak B; Bogoch E; Keystone EC; Fish EN
    J Rheumatol; 2003 May; 30(5):934-40. PubMed ID: 12734885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of intercellular adhesion molecule-1 expression on human synovial fibroblasts by endothelin-1.
    Iwabuchi H; Kasama T; Hanaoka R; Miwa Y; Hatano Y; Kobayashi K; Mori Y; Negishi M; Ide H; Adachi M
    J Rheumatol; 1999 Mar; 26(3):522-31. PubMed ID: 10090156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K.
    Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT
    J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
    Makrygiannakis D; af Klint E; Catrina SB; Botusan IR; Klareskog E; Klareskog L; Ulfgren AK; Catrina AI
    Arthritis Rheum; 2006 May; 54(5):1463-72. PubMed ID: 16646024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
    Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
    Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response.
    Marotte H; Maslinski W; Miossec P
    Arthritis Res Ther; 2005; 7(1):R149-55. PubMed ID: 15642135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand expression in fibroblast-like synoviocytes from rheumatoid arthritis and osteoarthritis patients.
    Harashima SI; Tsukamoto H; Horiuchi T
    Rheumatology (Oxford); 2004 Mar; 43(3):396-7; author reply 397. PubMed ID: 14963213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 47.